LYTIX.OL Lytix Biopharma AS
- Market cap
- NOK 612M
- P/E
- -
- P/B
- 6.92x
- ROE
- -121.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LYTIX.OL undervalued?
Graham numberThe Graham number of Lytix Biopharma AS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lytix Biopharma AS fundamental analysis
No fundamental analysis for Lytix Biopharma AS yet.
Lytix Biopharma AS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lytix Biopharma AS
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule i…
Full company profileLytix Biopharma AS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lytix Biopharma AS annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.06M | 337K | 310K | 3.00K | 17.0K | 1.41M | 3.99M | 11.1M | 0.00 | 0.00 |
| Operating Income | -63.8M | -62.4M | -33.8M | -42.4M | -48.0M | -65.7M | -96.8M | -95.9M | -64.0M | -107M |
| EBITDA | - | -62.4M | - | - | -48.0M | -55.9M | -86.9M | -93.2M | -58.8M | -106M |
| Net Income | -63.4M | -61.5M | -33.2M | -42.1M | -48.0M | -56.0M | -87.9M | -94.3M | -60.0M | -105M |
| EPS | -1.64 | -1.59 | -0.86 | -1.09 | -1.24 | -1.40 | -2.16 | -1.38 | -0.88 | -1.37 |
| Balance Sheet | ||||||||||
| Total Assets | 47.1M | 58.9M | 17.4M | 32.6M | 203M | 152M | 63.9M | 147M | 81.5M | 100M |
| Total Liabilities | 35.3M | 17.9M | 3.85M | 12.7M | 13.3M | 16.9M | 12.6M | 38.6M | 19.8M | 13.7M |
| Shareholders' Equity | 11.8M | 41.1M | 13.6M | 19.9M | 190M | 135M | 51.3M | 108M | 61.8M | 86.6M |
| Cash & Short-term Investments | 35.0M | 49.6M | 12.8M | 28.5M | 197M | 145M | 50.5M | 131M | 72.4M | 29.0M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -69.7M | -72.6M | -36.8M | -24.3M | -44.9M | -52.1M | -96.0M | -70.4M | -59.9M | -115M |
| Capital Expenditure | 0.00 | 0.00 | 154K | 154K | 154K | 154K | 49.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -72.6M | -36.8M | -24.3M | -44.9M | -52.3M | -96.0M | -70.4M | -59.9M | -115M |
| Ratios | ||||||||||
| ROE | -537.4% | -149.9% | -244.7% | -211.6% | -25.3% | -41.4% | -171.3% | -87.4% | -97.1% | -121.5% |
| ROA | -134.5% | -104.4% | -190.6% | -129.0% | -23.7% | -36.8% | -137.6% | -64.3% | -73.6% | -104.9% |
| Net Profit Margin | -5,982.6% | -18,253.7% | -10,718.4% | -1,402,933.3% | -282,641.2% | -3,974.9% | -2,202.4% | -846.6% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Lytix Biopharma AS dividends
Lytix Biopharma AS has not paid dividends in the last 9 fiscal years.
Last stock split: 1485:1478 on Jan 9, 2026.
Who owns Lytix Biopharma AS
- Insiders 52.67%
- Institutions 5.38%
- Public & others 41.95%
- Shares outstanding 76.9M
- Free float 40.2M
Lytix Biopharma AS company profile
- Company name
- Lytix Biopharma AS
- Ticker
- LYTIX.OL
- ISIN
- NO0010405780
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- Sandakerveien 138, Oslo, Norway, 0484
- Phone
- 47 95 26 05 12
- Website
- lytixbiopharma.com
About Lytix Biopharma AS
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.
Lytix Biopharma AS management
9- Dr. Oystein Rekdal Ph.D.Co-Founder & CEO
- Mr. Gjest Breistein M.Sc.Chief Financial Officer
- Dr. Mette Husbyn Ph.D.Chief Technology Officer
- Dr. Baldur Sveinbjørnsson Ph.D.Chief Scientific Officer
- Ms. Renee Christine AmundsenChief Operating Officer
- Mr. Ole Peter NordbyHead of IR & Communication Manager
- Jacqueline EarabinoHead of Clinical Operations
- Dr. Ahmed Bouzidi Ph.D.Senior VP of Business Development
- Mr. Timothy F. Herpin M.B.A., Ph.D.Chief Business Officer